Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram

International Clinical Psychopharmacology

Volumn 24, Issue 3, 2009, Pages 119-125

  Kasper, Siegfried ^a   Sacher, Julia ^a   Klein, Nikolas ^c   Mossaheb, Nilufar ^a   Attarbaschi Steiner, Trawat ^a   Lanzenberger, Rupert ^a   Spindelegger, Christoph ^a   Asenbaum, Susanne ^b   Holik, Alexander ^a   Dudczak, Robert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b University Clinic of Neurology   (Austria)

^c Praxisgemeinschaft Dr Georg Schoenbeck   (Austria)

Author keywords

Chiral switching; Citalopram; Escitalopram; Major depressive disorder; Selective serotonin reuptake inhibitors; Serotonin reuptake transporter occupancy; Serotonin transporters

Indexed keywords

CARBON 11; CITALOPRAM; ESCITALOPRAM; IODINE 123; PLACEBO; SEROTONIN TRANSPORTER; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENANTIOMER; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEADY STATE; COMPARATIVE STUDY; METABOLISM; STEREOISOMERISM; TISSUE DISTRIBUTION;

CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 67649231073     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32832a8ec8     Document Type: Review

References (56)

1. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-596.
2. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ (2002). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3:171-199.
3. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ (2002). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5-43.
4. Bel N, Artigas F (1992). Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 229:101-103.
5. Bel N, Artigas F (1993). Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 15:243-245.
6. Bel N, Artigas F (1995). In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain. Naunyn Schmiedebergs Arch Pharmacol 351:475-482.
7. Booij J, de Win MM (2006). Brain kinetics of the new selective serotonin transporter tracer [(123)I]ADAM in healthy young adults. Nucl Med Biol 33:185-191.
8. Brauner-Osborne H, Ebert B, Brann MR, Falch E, Krogsgaard-Larsen P (1996). Functional partial agonism at cloned human muscarinic acetylcholine receptors. Eur J Pharmacol 313:145-150.
9. Chen F, Larsen MB, Sanchez C, Wiborg O (2005). The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 15:193-198.
10. Choi SR, Hou C, Oya S, Mu M, Kung MP, Siciliano M, et al. (2000). Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. Synapse 38:403-412.
11. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758.
12. Dreshfield LJ, Wong DT, Perry KW, Engleman EA (1996). Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors. Neurochem Res 21:557-562.
13. 123I-ADAM for SPECT Studies on Humans. J Nucl Med 49:247-254.
14. Gorman JM, Korotzer A, Su G (2002). Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 7:40-44.
15. Haddjeri N, Blier P, de Montigny C (1998). Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 18:10150-10156.
16. Henry ME, Schmidt ME, Hennen J, Villafuerte RA, Butman ML, Tran P, et al. (2005). A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study. Neuropsychopharmacology 30:1576-1583.
17. Herold N, Uebelhack K, Franke L, Amthauer H, Luedemann L, Bruhn H, et al. (2006). Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM. J Neural Transm 113:659-670.
18. Hyttel J, Bogeso KP, Perregaard J, Sanchez C (1992). The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 88:157-160.
19. Kasper S, Vieira A, Schmidt R, Richter P (1990). Multiple hormone responses to stimulation with dl-fenfluramine in patients with major depression before and after antidepressive treatment. Pharmacopsychiatry 23:76-84.
20. Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Kufferle B, et al. (2002). Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder-implications for psychopharmacology. World J Biol Psychiatry 3:133-146.
21. Kasper S, Spadone C, Verpillat P, Angst J (2006). Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 21:105-110.
22. Kennedy SH, Andersen HF, Thase ME (2009). Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 25:161-175.
23. Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A, et al. (2005). Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol 32:123-128.
24. 123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl) 188:263-272.
25. 123I]ADAM SPECT study. Psychopharmacology (Berl) 191:333-339.
26. Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, et al. (2004). Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry 56:497-502.
27. Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, et al. (2007). Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 61:1081-1089.
28. 123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13:295-309.
29. Lepola UM, Loft H, Reines EH (2003). Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18:211-217.
30. Llorca PM, Azorin JM, Despiegel N, Verpillat P (2005). Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 59:268-275.
31. Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sanchez C, Haddjeri N (2007). Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. Int J Neuropsychopharmacol 10:31-40.
32. Meyer JH (2007). Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 32:86-102.
33. Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, et al. (2003). Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 160:90-99.
34. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826-835.
35. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, et al. (2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22:323-329.
36. Moore N, Verdoux H, Fantino B (2005). Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20:131-137.
37. Moret C, Briley M (1996). Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur J Pharmacol 295:189-197.
38. Mork A, Kreilgaard M, Sanchez C (2003). The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45:167-173.
39. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, et al. (2004). Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 24:589-591.
40. Nikisch G, Mathe AA, Czernik A, Eap CB, Jimenez-Vasquez P, Brawand-Amey M, Baumann P (2004). Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. J Clin Psychopharmacol 24:283-290
41. Pejchal T, Foley MA, Kosofsky BE, Waeber C (2002). Chronic fluoxetine treatment selectively uncouples raphe 5-HT(1A) receptors as measured by [(35)S]-GTP gamma S autoradiography. Br J Pharmacol 135:1115-1122.
42. Ramamoorthy S, Blakely RD (1999). Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285:763-766.
43. Ramamoorthy S, Giovanetti E, Qian Y, Blakely RD (1998). Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J Biol Chem 273:2458-2466.
44. Sanchez C, Kreilgaard M (2004). R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77:391-398.
45. Sanchez C, Gruca P, Bien E, Papp M (2003a). R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav 75:903-907.
46. Sanchez C, Gruca P, Papp M (2003b). R-citalopram counteracts the anti-depressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14:465-470.
47. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C (2004). Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 174:163-176.
48. 123I[ADAM] in healthy controls: a selective SERT radioligand. Int J Neuropsychopharmacol 10:211-218.
49. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F (1997). Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9:686-692.
50. 123I-ADAM. J Nucl Med 49: 176-178.
51. Storustovu S, Sanchez C, Porzgen P, Brennum LT, Larsen AK, Pulis M, Ebert B (2004). R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 142:172-180.
52. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002). Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7:317-321.
53. Whitworth TL, Herndon LC, Quick MW (2002). Psychostimulants differentially regulate serotonin transporter expression in thalamocortical neurons. J Neurosci 22:RC192.
54. 11C]-labeled 2-(phenylthio)araalkylamines. J Med Chem 43:3103-3110.
55. Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV (2007). Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a six-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 29:2319-2332.
56. Zhou FC, Tao-Cheng JH, Segu L, Patel T, Wang Y (1998). Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res 805:241-254.